News + Font Resize -

GSK buys sanofi-aventis' injectable anti-thrombotic agents
London | Thursday, September 2, 2004, 08:00 Hrs  [IST]

GlaxoSmithKline plc (GSK) acquired, on a worldwide basis, the injectable anti-thrombotic agents Fraxiparine, Fraxodi and Arixtra and related assets including a manufacturing facility located in Notre-Dame de Bondeville, France from Sanofi-Aventis. As part of this transaction, GSK assumes responsibility for ongoing Arixtra clinical trials.

The closing of this divestiture transaction follows Sanofi-Synthelabo's successful completion of its offer for Aventis, after obtaining the requisite clearances from EU and US competition authorities.

Fraxiparine (nadroparine calcium) is a Low Molecular Weight Heparin and Arixtra (fondaparinux sodium) is a selective factor Xa inhibitor. Sales of Fraxiparine were EUR 319 million in 2003. Worldwide sales of Arixtra were EUR 24 million in 2003.

The manufacturing facility located in Notre-Dame de Bondeville, France is engaged mainly in the manufacture of Fraxiparine and Arixtra injectable products. This facility employs approximately 650 people.

Pharmaceuticals Europe president, Andrew Witty said: "We are very pleased with this acquisition. These are great products which will provide GSK with good commercial opportunities and help strengthen our portfolio in the hospital business."

Post Your Comment

 

Enquiry Form